Dementia and age-related cognitive decline present a looming public health challenge worldwide, with incidence rates expected to climb sharply as global populations age. Concurrently, hypertension affects nearly half of adults in the United States and has earned the moniker “silent killer” for its asymptomatic yet devastating impact. Significantly, hypertension stands out not only as a driver of cardiovascular disease but also as a modifiable risk factor for cognitive impairment, suggesting that blood pressure management may hold the key to preserving brain health over the lifespan.

The 2025 ACC/AHA Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults elevates blood pressure control as the foremost modifiable risk factor in preventing cardiovascular diseases and vascular dementia. It emphasizes the vascular damage wrought by uncontrolled hypertension in the brain, linking cerebrovascular health and cognitive decline more explicitly than ever before. These developments challenge healthcare providers to rethink the timing and strategies for hypertension treatment, focusing on early intervention.

At the forefront of this research, Dr. Newton Nyirenda, an epidemiologist at Georgetown University, emphasizes that blood pressure management transcends traditional cardiovascular endpoints. “Our findings suggest that managing hypertension is among the most actionable approaches to safeguarding cognitive function,” Dr. Nyirenda explains. The studies advocate for a paradigm shift toward earlier monitoring and intervention in younger adults, aiming to forestall the vascular damage that predisposes to dementia later in life.

Two pivotal studies examined participants’ vascular aging patterns over time, leveraging novel indices derived from readily available clinical data. The first highlighted the pulse pressure-heart rate index, a composite metric calculated from heart rate and blood pressure values, demonstrating its independent predictive power for dementia risk in individuals over 50. This metric captures the dynamic interplay between cardiac output and arterial compliance, reflecting vascular health more sensitively than conventional blood pressure measures alone.

In a complementary study, researchers investigated the trajectory of estimated pulse wave velocity (PWV), a validated surrogate of arterial stiffness that encapsulates the progressive loss of vascular elasticity with age. PWV was derived using age and traditional blood pressure measurements, offering a non-invasive and scalable approach to assess vascular aging. Adults with persistently elevated or rapidly increasing PWV exhibited a significantly heightened likelihood of developing dementia compared to those with stable vascular profiles, underscoring the role of progressive arterial stiffening in cognitive decline.

These insights derive from a rigorous analysis of 8,536 subjects from the SPRINT trial, one of the largest hypertension-focused clinical cohorts, involving adults over 50 years old with elevated cardiovascular risk. Over five years of follow-up, 323 participants developed probable dementia, allowing researchers to correlate vascular aging indices with incident cognitive impairment robustly. The granular longitudinal data enabled identification of specific vascular trajectories linked with dementia, providing a foundation for risk stratification.

Importantly, the magnitude of risk associated with these indices is substantial. An increase of just one unit in the pulse pressure-heart rate index before the age of 65 correlated with a 76% higher risk of developing probable dementia or mild cognitive impairment. Similarly, elevated PWV patterns predicted dementia risk independently of several confounding factors including age, sex, presence of kidney disease, cardiovascular history, and smoking status. These findings highlight arterial stiffness as a potent biomarker and potential therapeutic target.

Clinicians stand to benefit from integrating these accessible metrics into routine care. Since pulse pressure-heart rate index and estimated pulse wave velocity rely on standard measurements typically collected during primary care visits, adoption into clinical workflows could be seamless. By quantifying vascular aging and communicating dementia risk in tangible terms, healthcare providers may enhance patient motivation to adopt lifestyle modifications and adhere to antihypertensive therapies, ultimately improving both heart and brain outcomes.

Dr. Sula Mazimba, associated with the University of Virginia, stresses the need for individualized patient assessments. “Intervening before cognitive symptoms manifest is crucial—waiting until decline occurs is far too late,” Dr. Mazimba notes. This proactive approach recognizes dementia prevention as an extension of cardiovascular risk management, bridging specialties and fostering comprehensive patient-centered care.

Nonetheless, the observational design of these analyses, performed as post hoc studies within a randomized clinical trial, precludes definitive conclusions about causation. The specific cohort—individuals with hypertension and elevated cardiovascular risk—may limit generalizability to broader or lower-risk populations. There remains a pressing need for prospective trials to validate clinically actionable thresholds for these indices and to test whether modifying vascular aging trajectories can tangibly reduce dementia incidence.

As researchers continue to unravel the complex vascular underpinnings of dementia, this body of work signals a transformative opportunity to harness routine cardiovascular assessments for dual purposes: preventing heart disease and staving off cognitive decline. The convergence of vascular biology and neurodegeneration research paves the way for refined preventive strategies that could alter the course of aging for millions worldwide.

In conclusion, these findings compel a reassessment of blood pressure management paradigms. They call for earlier, more nuanced surveillance of vascular health using innovative yet simple indices, fostering integrated strategies that prioritize long-term brain health alongside cardiovascular protection. As dementia continues its rise as a global health challenge, leveraging vascular aging markers unlocks a promising pathway to delay or prevent the disabling cognitive declines that undermine quality of life in aging populations.

Subject of Research: Vascular aging markers derived from blood pressure readings as predictors of dementia risk
Article Title: Measures of Blood Vessel Health Predict Dementia Risk: Insights from SPRINT Trial Analyses
News Publication Date: March 2026 (corresponding to ACC.26 presentation)
Web References:
– American College of Cardiology 2025 ACC/AHA Hypertension Guideline: https://www.jacc.org/doi/10.1016/j.jacc.2025.05.007
– CardioSmart Blood Pressure Resources: www.CardioSmart.org/BloodPressure
Keywords: vascular aging, arterial stiffness, pulse wave velocity, pulse pressure-heart rate index, hypertension, dementia risk, cognitive decline, SPRINT trial, blood pressure management, cardiovascular health, neurocognitive preservation

The trial is notable for being the first to administer empagliflozin—a drug primarily used for diabetes and cardiovascular health—to non-diabetic patients with Alzheimer’s. Empagliflozin belongs to the class of sodium-glucose cotransporter 2 (SGLT2) inhibitors, which helps regulate glucose reabsorption in the kidneys, thereby improving systemic insulin sensitivity and cardiovascular outcomes. The decision to investigate it in a neurological context stems from growing evidence that metabolic dysfunction and vascular impairment are critical drivers in the pathogenesis of Alzheimer’s, beyond the classical amyloid-beta and tau protein perspectives.

Alzheimer’s disease has long been characterized by accumulations of amyloid plaques and tau tangles in the brain, but recent emphasis on metabolic and vascular contributors provides a fresh frontier for therapeutic strategies. Traditional anti-amyloid medications, while a significant step forward, offer only modest benefits and are restricted in use due to side effects and contraindications. These drugs also fail to address upstream dysfunctions in brain metabolism and blood flow, which fuel neurodegeneration and cognitive decline. Thus, the Wake Forest study positions metabolism as a strategic target to slow or potentially halt disease progression.

Led by Suzanne Craft, Ph.D., director of the Wake Forest Alzheimer’s Disease Research Center, the study enrolled a cohort of 47 older adults averaging 70 years of age. Participants with mild cognitive impairment or early Alzheimer’s were randomized into four groups: intranasal insulin alone, empagliflozin alone, both drugs combined, or placebo. The trial’s design meticulously aimed at dissecting the differential and potentially synergistic impacts of these metabolic modulators on brain function and pathology.

Intranasal insulin was administered through a novel, precision-engineered cartridge pump device developed by Aptar Pharma, designed to deliver the peptide hormone directly into the central nervous system via the nasal-olfactory route. This delivery circumvents the systemic circulation and blood-brain barrier, enabling targeted activation of insulin receptors across synapses, vasculature, and glial support cells. Insulin signaling in the brain plays a pivotal role in maintaining synaptic plasticity, cerebral blood flow, white matter integrity, and immune regulation—all processes impaired in Alzheimer’s pathology.

Over the course of four weeks, the intranasal insulin group exhibited significant cognitive enhancements, particularly in sensitive tasks assessing memory and executive functions, areas commonly compromised in early Alzheimer’s. Neuroimaging confirmed increased white matter structural integrity and modulated regional cerebral blood flow patterns in areas critical to memory. Moreover, the treatment lowered levels of plasma glial fibrillary acidic protein (GFAP), an astrocyte dysfunction biomarker implicated in neuroinflammatory responses and blood-brain barrier disruption.

In contrast, empagliflozin showed a distinct yet complementary biochemical effect. Cerebrospinal fluid analyses revealed a marked reduction in tau protein concentrations, a hallmark of AD neurofibrillary degeneration. Additionally, decreases in neurogranin—a postsynaptic protein involved in synaptic plasticity—and vascular injury markers suggest empagliflozin acts to mitigate synaptic loss and microvascular dysfunction, key drivers in cognitive decline. The drug’s capacity to elevate high-density lipoprotein (HDL) cholesterol further confirms its broad metabolic benefits, extending beyond glycemic control into neurovascular health.

Interestingly, both medications exerted immunomodulatory effects, influencing cerebrospinal fluid and systemic inflammatory mediator levels. The data indicate activation of protective immune pathways while dampening deleterious neuroinflammation, a central component of Alzheimer’s pathophysiology. The unique impact of intranasal insulin on proteins associated with the nasal-olfactory plexus highlights its potential to leverage the brain’s glymphatic and immune clearance systems, which are increasingly recognized for their roles in waste removal and neuroimmune communication.

This bifurcated mechanism—empagliflozin’s systemic metabolic and vascular enhancement paired with intranasal insulin’s direct neurotrophic and immune-modulating actions—offers a complementary therapeutic paradigm. Empagliflozin’s ability to reduce oxidative stress and support mitochondrial energetics further bolsters cellular resilience against degenerative insults, while intranasal insulin promotes synaptic maintenance and vascular regulation critical for cognitive preservation.

The clinical trial affirmed the safety and tolerability of both agents in non-diabetic participants, with high adherence rates and minimal mild side effects uniformly across study arms. The intranasal device received excellent user acceptability scores, crucial for potential long-term treatment feasibility. Despite the relatively short duration of four weeks, these mechanistic and functional changes provide compelling evidence for extending and scaling such interventions.

Looking forward, the research team plans to pursue larger, longer-duration studies, including subjects in preclinical stages of Alzheimer’s, to validate and expand upon these encouraging findings. The prospect of combining metabolic modulators like empagliflozin and intranasal insulin with existing and emerging Alzheimer’s therapies may revolutionize the treatment landscape, offering personalized, multifaceted strategies that target the diverse pathological processes driving this disease.

Because both empagliflozin and intranasal insulin are FDA-approved for other indications with established safety profiles, their repurposing for Alzheimer’s could expedite clinical availability, an urgent need in a field where therapeutic options remain limited. This study exemplifies a promising shift towards addressing the metabolic and vascular roots of neurodegeneration rather than solely focusing on amyloid and tau pathology.

The research was generously funded by the Alzheimer’s Association’s “Part the Cloud” initiative, which supports innovative clinical trials aimed at slowing, stopping, or curing Alzheimer’s disease. This philanthropic effort, sparked by Michaela “Mikey” Hoag and others, has mobilized nearly $90 million to propel diverse investigational treatments through clinical pipelines, reflecting the complex and multifactorial nature of Alzheimer’s requiring tailored combination therapies.

In summary, the Wake Forest trial offers compelling evidence that targeting brain metabolism and vascular health using empagliflozin and intranasal insulin can modulate pathological markers, improve cognition, and normalize neurovascular and immune functions in early Alzheimer’s disease. These promising metabolic modulators could help close the significant therapeutic gaps unaddressed by existing Alzheimer’s treatments, heralding a new era of precision medicine in neurodegenerative disease management.

Subject of Research: People

Article Title: A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD

News Publication Date: October 16, 2025

Web References:

• Alzheimer’s & Dementia Journal Article
• Wake Forest University School of Medicine

Keywords: Alzheimer disease, neurodegenerative diseases, dementia, diabetes, insulin

The research team meticulously examined a range of cognitive test scores, focusing particularly on verbal fluency and memory, two domains vulnerable to age-related deterioration. Over a six-year period following smoking cessation, participants who quit showed a markedly slower decline in these cognitive faculties compared to their counterparts who kept smoking. Specifically, the decline in verbal fluency was reduced by approximately 50%, while memory decline slowed by about 20%. Such findings underscore a significant cognitive preservation linked to quitting smoking, even in middle and older ages.

Understanding the mechanism underlying these observations is complex, yet pivotal. Smoking is known to inflict damage on cardiovascular health, deteriorating the blood vessels responsible for oxygen delivery to the brain. This vascular impairment can accelerate neurodegeneration. Beyond vascular effects, tobacco smoke induces chronic systemic inflammation and generates oxidative stress through the production of reactive free radicals, both of which directly compromise neuronal integrity and function. Consequently, smoking exerts a multifaceted assault on cognitive health.

Dr. Mikaela Bloomberg, lead author from UCL’s Institute of Epidemiology & Health Care, emphasized the public health significance of these findings. She notes that quitting smoking can help maintain cognitive function even when cessation occurs after age 50. Given that middle-aged and older smokers tend to have lower quit rates despite bearing a disproportionate burden of smoking-related harm, this new evidence could serve as a potent motivator to encourage smoking cessation in this demographic.

The study’s robust design involved longitudinal data from three large-scale surveys: the English Longitudinal Study of Ageing (ELSA), the Survey of Health, Ageing and Retirement in Europe (SHARE), and the Health and Retirement Study (HRS) in the United States. These cohorts provided nationally representative samples that were repeatedly assessed every two years, permitting an in-depth analysis of cognitive trajectories before and after smoking cessation.

A unique strength of the study was the use of matched control groups, whereby over 4,700 individuals who quit smoking were compared to an equal number of those who continued. Matching accounted for baseline cognitive scores, age, sex, education, and country of birth to minimize confounding factors. Prior to quitting, both groups exhibited similar cognitive decline rates, establishing a solid baseline for comparison. This methodological rigor enhances confidence in the association between smoking cessation and slower cognitive decline.

Quantitatively, the cognitive benefits of quitting smoking translated to approximately three to four fewer months of memory decline and six months less decline in verbal fluency per year of aging, compared to smokers who did not quit. This is particularly meaningful in the context of aging populations, where even modest deceleration of cognitive deterioration can substantially impact quality of life, independence, and overall dementia risk.

However, the authors cautiously acknowledge the study’s observational nature, underscoring that while the results are consistent and compelling, causality cannot be definitively established. Unmeasured variables and lifestyle differences between those who quit and those who did not could influence outcomes. Nonetheless, the findings align with prior research showing that cognitive function improves shortly after smoking cessation and that long-term quitters match the cognitive performance of never-smokers.

Smoking cessation’s impact on brain health extends beyond cognitive test scores to encompass dementia risk. Slower cognitive decline correlates strongly with a reduced probability of developing neurodegenerative diseases such as Alzheimer’s. Professor Andrew Steptoe, co-author of the study, highlighted this connection, stressing that these results support the notion that quitting may be a viable preventative strategy against dementia, warranting further targeted research.

The implications of these findings are far-reaching. With global populations aging rapidly and dementia emerging as a major public health challenge, interventions that can preserve cognitive health are urgently needed. Tobacco control thus becomes not only a disease prevention strategy but also a means to enhance brain health and cognitive longevity, reinforcing the call for stronger public health policies and cessation programs aimed at older smokers.

In practical terms, this study offers hope and actionable guidance: it is never too late to quit smoking for cognitive benefit. Healthcare providers and policymakers should leverage these insights to intensify cessation support tailored to middle-aged and older adults. Behavioral intervention programs and public messaging could be recalibrated to emphasize cognitive health benefits, potentially improving quit rates in a population segment that traditionally shows resistance to quitting.

Furthermore, this research contributes to the growing interdisciplinary understanding of how lifestyle factors interact with brain aging. Integrating knowledge from epidemiology, neurology, and public health paints a more comprehensive picture of modifiable risk factors affecting cognitive trajectories. Future investigations are encouraged to delve deeper into biological mechanisms and to explore whether similar benefits can be observed in cognitive domains beyond memory and verbal fluency.

The scientific community eagerly anticipates subsequent studies that will elucidate the relationship between smoking cessation and neurodegenerative disease incidence directly. Such work will be critical in translating observational associations into clinical recommendations and in refining guidelines for dementia prevention strategies linked with lifestyle modification.

Overall, this study is a landmark contribution to cognitive epidemiology, reinforcing the profound and enduring impact of smoking cessation on brain health. By slowing cognitive decline, quitting smoking emerges as a vital strategy not only for cardiovascular and respiratory well-being but also for maintaining mental acuity and reducing the burden of dementia in aging societies.

Subject of Research: Impact of smoking cessation on cognitive decline and brain health in middle-aged and older adults

Article Title: Not explicitly provided in the source content

News Publication Date: Not explicitly provided in the source content

Web References: DOI link

References: English Longitudinal Study of Ageing (ELSA), Survey of Health, Ageing and Retirement in Europe (SHARE), Health and Retirement Study (HRS)

Keywords: Cognitive function, Memory, Health and medicine

Resting heart rate variability refers to the natural variations in the time intervals between heartbeats, reflecting the dynamic interplay of the autonomic nervous system’s sympathetic and parasympathetic branches. Traditionally, RHRV has been associated with cardiovascular health, with reduced variability often signaling increased risk for heart disease. However, the present study extends this concept to neurocognitive domains, proposing that long-term visit-to-visit variability in resting heart rate carries significant implications for brain health and cognitive aging.

The research team utilized variation independent of mean (VIM) as the principal metric for assessing RHRV, a refined measure that accounts for average heart rate levels and focuses more precisely on the variability component. Pooling data from a combined total of 11,667 participants—7,582 from HRS and 4,085 from CHARLS—enabled the study to achieve a remarkable statistical power and cross-cultural relevance. Participants were required to have multiple resting heart rate measurements across different visits, ensuring the robustness of the visit-to-visit variability assessment.

Cognitive function was evaluated using a battery of neuropsychological tests standardized across both cohorts. These tests probed multiple domains, including memory retention, selective attention, and temporal-spatial orientation. To synthesize these scores, the researchers computed a standardized Z-score reflecting global cognitive ability. The longitudinal design allowed for tracking changes in cognitive function over time, critical for understanding the dynamics between RHRV and cognitive trajectories rather than static snapshots.

Using linear mixed models, which accommodate both fixed effects and individual variability over time, the researchers identified consistent, statistically significant negative associations between higher VIM of RHRV and cognitive performance. Specifically, each standard deviation increase in VIM corresponded to a decline in global cognitive functioning—β values of −0.022 in the HRS cohort and −0.023 in CHARLS—pointing to a robust, replicable relationship across diverse populations.

Further reinforcing their findings, the study implemented several sensitivity analyses. Alternative measures of RHRV, such as average real variability and coefficient of variation, yielded consistent results, indicating that the association is not circumscribed to a single metric but reflects a genuine physiological phenomenon. Moreover, adjustments for lifestyle factors such as physical activity, as well as health confounders including pre-existing cardiovascular conditions and systemic inflammation markers like C-reactive protein, did not substantially alter the observed relationships. This implies that RHRV’s link to cognitive decline operates independently of these common confounds.

These results add a crucial layer of understanding to the complex interrelationship between cardiovascular dynamics and neurodegeneration. Previous studies have often focused on episodic or short-term heart rate variability, but this investigation highlights the importance of long-term visit-to-visit fluctuations. Such variability may be indicative of underlying autonomic dysregulation or vascular instability, which in turn could affect cerebral blood flow and neural network function, gradually impairing cognition.

The implications are profound for early detection and prevention strategies aimed at cognitive decline and dementia. Monitoring long-term RHRV patterns could serve as a non-invasive biomarker, allowing healthcare providers to identify at-risk individuals well before overt symptoms of cognitive impairment emerge. This approach aligns with the growing field of precision medicine, leveraging longitudinal physiological data to tailor interventions and possibly slow down the progression of cognitive illnesses.

Furthermore, the study bridges a critical gap by incorporating data from two national cohorts with differing genetic backgrounds, environmental exposures, and healthcare systems. The consistency across the U.S.-based HRS and China’s CHARLS underscores the potential universality of RHRV’s predictive capacity, suggesting similar biological mechanisms may be at play globally, transcending cultural and ethnic differences.

While the study presents compelling epidemiological evidence, the authors call for further mechanistic investigations to unravel the precise biological pathways linking heart rate variability fluctuations to neural decline. Possible candidates include chronic stress responses mediated by the autonomic nervous system, endothelial dysfunction affecting cerebral microvasculature, or systemic inflammation that impairs neuroplasticity. Understanding these mechanistic underpinnings will be crucial for developing targeted therapeutics.

In summary, this pioneering research illuminates the promising frontier where cardiology intersects with cognitive aging. By leveraging long-term visit-to-visit RHRV as a dynamic physiological marker, clinicians and scientists gain a novel tool for early identification of cognitive vulnerability. Coupled with traditional risk assessments, RHRV monitoring could revolutionize how we approach brain health maintenance in aging populations, offering hope for mitigating the burdens of dementia and cognitive impairment worldwide.

Given the rapidly aging global population and the escalating public health challenge posed by cognitive disorders, such integrative biomarker approaches are both timely and essential. This study not only expands the landscape of cardiovascular biomarkers but also heralds a new paradigm in understanding and managing cognitive decline through longitudinal physiological data.

As the field advances, integrating wearable technologies and continuous monitoring devices capable of capturing heart rate variability outside clinical settings will enhance the feasibility and scalability of RHRV-based cognitive risk assessments. Such innovations promise to democratize access to precision cognitive diagnostics, enabling proactive brain health interventions at the population level.

Finally, the confluence of cardiovascular and cognitive research embodied in this study sets the stage for interdisciplinary collaborations. Neuroscientists, cardiologists, epidemiologists, and data scientists stand to benefit from these findings, synergizing their expertise to decode the complex biological narratives connecting heart rhythms and mind function over the human lifespan.

Subject of Research: The association between long-term visit-to-visit resting heart rate variability (RHRV) and cognitive decline in aging populations.

Article Title: Association between long-term visit-to-visit resting heart rate variability and cognitive decline: evidence from two national cohorts.

Article References:
Zheng, G., Zhou, B., Fang, Z. et al. Association between long-term visit-to-visit resting heart rate variability and cognitive decline: evidence from two national cohorts. BMC Psychiatry 25, 751 (2025). https://doi.org/10.1186/s12888-025-07208-1

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07208-1